Advanced Cell Technology to Present at Regen Med Investor Day 2013

  Advanced Cell Technology to Present at Regen Med Investor Day 2013

Business Wire

MARLBOROUGH, Mass. -- April 16, 2013

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of
regenerative medicine, today announced that Chairman and CEO Gary Rabin will
present at the Alliance for Regenerative Medicine’s first annual Regen Med
Investor Day on Wednesday, April 17, 2013 in New York City.

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with
financial firms Burrill & Company, Maxim Group and Piper Jaffray, this
flagship event features 16 of the regenerative medicine field’s leading
companies. In addition, there will be disease indication-focused discussions
between key opinion leaders, top analysts and senior executives from the
sector, and keynote-style talks by Jeff Jonas, president of Shire Regenerative
Medicine, and Kieran Murphy, president and CEO, GE Healthcare Life Sciences.

The following are specific details regarding ACT’s presentation at the
conference:

   Event:       ACT Presentation at ARM’s Regen Med Investor Day
                      
      Date:           Wednesday, April 17, 2013
                      
      Time:           3:45 p.m. EDT
                      
      Location:       Harmonie Club, 4 East 60th Street, New York, NY 10022

A live video webcast of all company presentations will be available at
http://alliancerm.org/rmdaywebcast and will also be published on ARM’s website
shortly after the event.

A copy of Mr. Rabin’s presentation will be available on the presentations
section of the ACT website.

Attendance at this event is for credentialed investors and members of the
media only. If you are interested in attending, please contact Laura Parsons
at lparsons@alliancerm.org. Please visit
http://alliancerm.org/event/regen-med-investor-day for more information.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2012. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
 
Press spacebar to pause and continue. Press esc to stop.